Prostatis Group LLC Zynerba Pharmaceuticals, Inc. Transaction History

Prostatis Group LLC

  • $215 Billion
  • Q2 2023

Shares

3 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2020

Mar 23, 2023
SELL
$3.23 - $4.3 $32,655 - $43,473
-10,110 Closed
0 $0
Q2 2020

Mar 23, 2023
SELL
$3.31 - $6.54 $4,567 - $9,025
-1,380 Reduced 12.01%
10,110 $10.1 Million
Q1 2020

Mar 23, 2023
BUY
$2.9 - $6.16 $33,321 - $70,778
11,490 New
11,490 $11.5 Million

Others Institutions Holding ZYNE

# of Institutions
4
Shares Held
774K
Call Options Held
0
Put Options Held
0
View Full List

About Zynerba Pharmaceuticals, Inc.

ZYNE Quotes by TradingView
  • Ticker ZYNE
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Drug Manufacturers—Specialty & Generic
  • Shares Outstandng 45,753,100
  • Description
  • Zynerba Pharmaceuticals, Inc. operates as a clinical stage specialty pharmaceutical company. The company focuses on developing pharmaceutically-produced transdermal cannabinoid therapies for rare and near-rare neuropsychiatric disorders. It is developing Zygel, a pharmaceutically-produced cannabidiol formulated as a permeation-enhanced gel for t...
More about ZYNE
Track This Portfolio

Track Prostatis Group LLC Portfolio

Follow Prostatis Group LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Prostatis Group LLC, based on Form 13F filings with the SEC.

News

Stay updated on Prostatis Group LLC with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email